186 related articles for article (PubMed ID: 9580814)
1. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatment with liposomal amphotericin B.
Roustan G; Jiménez JA; Gutiérrez-Solar B; Gallego JL; Alvar J; Patrón M
Br J Dermatol; 1998 Mar; 138(3):526-8. PubMed ID: 9580814
[TBL] [Abstract][Full Text] [Related]
2. Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B.
Hashim FA; Khalil EA; Ismail A; el Hassan AM
Trans R Soc Trop Med Hyg; 1995; 89(4):440. PubMed ID: 7570893
[No Abstract] [Full Text] [Related]
3. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
5. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
[TBL] [Abstract][Full Text] [Related]
6. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
[TBL] [Abstract][Full Text] [Related]
9. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
[TBL] [Abstract][Full Text] [Related]
10. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Treatment of Widespread Nodular Post kala-Azar Dermal Leishmaniasis with Extended-Dose Liposomal Amphotericin B in Bangladesh: A Series of Four Cases.
Basher A; Maruf S; Nath P; Hasnain MG; Mukit MA; Anuwarul A; Aktar F; Nath R; Hossain AA; Milton AH; Mondal D; Mohammad Sumsuzzaman AK; Rahman R; Faiz MA
Am J Trop Med Hyg; 2017 Oct; 97(4):1111-1115. PubMed ID: 28820697
[TBL] [Abstract][Full Text] [Related]
12. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
[TBL] [Abstract][Full Text] [Related]
13. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
14. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
16. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
18. High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis.
Gasim S; Theander TG; ElHassan AM
Acta Trop; 2000 Feb; 75(1):35-8. PubMed ID: 10708005
[TBL] [Abstract][Full Text] [Related]
19. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis.
Zijlstra EE; Khalil EA; Kager PA; El-Hassan AM
Br J Dermatol; 2000 Jul; 143(1):136-43. PubMed ID: 10886148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
